Table 2

Immunohistochemical analysis of human pancreatic carcinoma in the pancreas of control and treated nude mice

Treatment groupaTumor cellsEndothelial cells
PCNA+TUNEL+VEGFIL-8CD31+% TUNEL+
Control594 ± 47b13 ± 6b265 ± 21c235 ± 7c82 ± 25b1.6d
Gemcitabine353 ± 1847 ± 13e245 ± 35165 ± 7e65 ± 12.6
PKI 166, 3 days/wk165 ± 4e71 ± 8f180 ± 10e175 ± 7e37 ± 4e20e
PKI 166, 7 days/wk95 ± 25e100 ± 20f145 ± 7e170 ± 14e29 ± 6e22e
PKI 166, 3 days/wk + gemcitabine84 ± 14e85 ± 13f143 ± 15e160 ± 14e9 ± 3f27f
PKI 166, 7 days/wk + gemcitabine85 ± 13e127 ± 17f124 ± 28e155 ± 7e8 ± 1f30f
  • a L3.6pl human pancreatic cancer cells (1 × 106) were injected into the pancreas of nude mice. Seven days later, groups of mice were treated with biweekly i.p. injections of gemcitabine (125 mg/kg) alone, daily (3 or 7 days a week) oral feedings of PKI 166 (50 mg/kg) alone, PKI 166 in combination with gemcitabine, or saline (control). All mice were killed on day 35.

  • b The number (mean ± SD) of positive cells/field determined from measurement of 10 random 0.159-mm2 fields at ×100 magnification.

  • c Mean ± SD absorbance, determined as described in “Materials and Methods.”

  • d The number (mean ± SD) of CD31/TUNEL-positive cells in 10 random 0.011-mm2 fields at ×400 magnification. Fluorescent double labeling was performed on frozen tissue sections.

  • e P < 0.05 as compared with controls.

  • f P < 0.001 as compared with controls.